More impactful benefit changes coming in 2025; will destabilization among standalone plans follow?

Launching much faster than it told a US FDA advisory committee that it would, Sarepta is focusing on Duchenne muscular dystrophy patients about to turn six in the initial roll-out of its gene therapy Elevidys amid fears the wait for payer authorization could mean losing access to the treatment.

Teva’s counsel notes a key factor in the jury's finding that Gilead’s patent settlement with Teva did not include a reverse payment to delay entry of Truvada and Atripla generics. A second trial will proceed on claims a collaboration agreement between Gilead and Janssen was anticompetitive.

Hospital procedures are rebounding following the pandemic and the US population is aging. But what sounds like good news for pharma is curbed by the risk of Medicare insolvency, and suing the government cannot solve that.